DAVENPORT & Co LLC Sells 500 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

DAVENPORT & Co LLC decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 8.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 5,433 shares of the company’s stock after selling 500 shares during the quarter. DAVENPORT & Co LLC’s holdings in Henry Schein were worth $411,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. acquired a new position in Henry Schein during the 4th quarter valued at about $39,000. Baystate Wealth Management LLC lifted its holdings in Henry Schein by 2,500.0% in the third quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Neo Ivy Capital Management bought a new position in shares of Henry Schein in the 3rd quarter worth $46,000. Covestor Ltd boosted its holdings in Henry Schein by 88.4% during the first quarter. Covestor Ltd now owns 861 shares of the company’s stock worth $75,000 after buying an additional 404 shares during the last quarter. Finally, RVW Wealth LLC acquired a new position in Henry Schein during the third quarter valued at approximately $104,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Up 1.0 %

Shares of HSIC stock opened at $73.17 on Wednesday. The firm’s fifty day moving average price is $75.05 and its two-hundred day moving average price is $72.61. Henry Schein, Inc. has a 1 year low of $60.01 and a 1 year high of $85.75. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $9.40 billion, a P/E ratio of 23.23, a PEG ratio of 1.80 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. During the same period in the prior year, the firm posted $1.21 EPS. Henry Schein’s revenue was down 10.5% compared to the same quarter last year. On average, equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Insider Activity at Henry Schein

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler raised their price objective on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. JPMorgan Chase & Co. lifted their price target on shares of Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. SVB Leerink started coverage on shares of Henry Schein in a report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective on the stock. TheStreet raised shares of Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. Finally, Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Henry Schein presently has an average rating of “Hold” and a consensus target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.